PlexusDx analyzes your GLP1R and GIPR genetic variants through the Precision Peptide Genetic Test ($99 add-on after first month) to map your individual peptide pathway
There are currently no established safety data specifically addressing GLP-1 agonist use in active Crohn's disease, requiring thorough informed consent, close monitoring, and coordination between specialists
No clinical trials have studied sublingual tirzepatide in humans, so effectiveness claims rely entirely on anecdotal reports rather than scientific evidence
Novo Nordisk (NVO) Trailing P/Es: LLY 38, NOV 10 Forward P/Es: LLY 26, NVO 11 Estimated 2026 sales growth: LLY 26%, NVO -8% Estimated 2025 EPS growth: LLY 43%, NVO -6% Cash per share: LLY $8.14, NVO $6.07 Institutional ownership: LLY 84.6%, NVO 9.5% In terms of value, NVO has LLY beat by a mile, trading at less than a third of LLY on a trailing price-to-earnings basis and just under half of it on a forward price-to-earnings basis
